thymosin beta-4 · Tβ4 · timbetasin
This name is used for thymosin beta-4 or a short piece of it. A test of products sold online found contents that did not match their description.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
Safety. Studies of thymosin beta-4 do not test this fragment. A 2026 review says very little is known about the safety of peptides like this one in people. Sources: study 1.
Risk of fakes. A lab test found that TB500 and TB1000 products do not match their earlier descriptions. Sources: study 1, study 2, study 3, study 4.
| Where | Status | Checked | |
|---|---|---|---|
| PL | No approval | The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source | Not yet |
| EU | No approval | The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source | Not yet |
| US | No approval | No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026. Source | Not yet |
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
Not clear. In one study of tendons in rats, TB-500 improved early healing. There is no study of this fragment in people.
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
| Most often reported | Reports |
|---|---|
| Low insulin in the blood | 1 |
| High potassium in the blood | 1 |
| Raised liver enzymes | 1 |
| Abnormal histamine level | 1 |
| High blood pressure | 1 |
| Slow stomach emptying | 1 |
| Feeling generally unwell | 1 |
| Lymph cancer | 1 |
Serious means the person went to hospital, their life was in danger, they were left with lasting harm, or they died. One report can list several side effects.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
Two pain medicine specialists go through the studies on BPC-157, TB-500, MOTS-c and GHK-Cu, the risk of contaminated products bought online, including heavy metals, and why a doctor should assess you first.
A coach responds to the Nippard video. According to the chapters in the description, he covers GLP-1 medicines using a client as an example, then BPC-157 and TB-500, the risk of products without quality control, and why to be sceptical of the claims.
The description has ads
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. | In animals | rats, Achilles tendon transection and repair | 32 | 4 wk | – | Unknown |
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
The US health department published a draft policy under which it would not act against pharmacies that make TB-500 on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
